MarketCap
Facebook
X
TelegramQuarterly report 2023-Q3
added 11-20-2023
Acer Therapeutics ROE Ratio 2011-2026 | ACER
Annual ROE Ratio Acer Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 156.54 | 891.97 | -278.27 | -160.14 | -47.2 | -63.55 | -294.9 | -125.0 | -202.34 | -80.95 | -309.74 | -82.95 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 891.97 | -309.74 | -49.71 |
Quarterly ROE Ratio Acer Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 158.55 | 168.71 | 174.74 | 162.25 | 11.03 | -181.2 | -275.01 | -277.73 | -349.82 | -270.68 | -277.4 | -202.42 | -231.01 | -187.51 | -177.45 | -132.07 | -140.87 | -121.08 | -71.7 | -28.36 | -43.93 | -50.71 | -53.96 | -44.68 | -26.17 | 7.91 | -55.89 | -139.11 | -168.16 | -215.73 | -167.01 | -92.97 | -145.1 | -168.17 | -195.07 | -157.23 | -185.05 | -160.74 | -119.33 | -62.68 | -144.45 | -198.41 | -258.92 | -239.18 | -257.21 | -193.47 | -139.05 | -56.86 | -18.03 | -20.66 | -18.18 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 174.74 | -349.82 | -118.38 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B |  France |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M | France |
 |
Ascendis Pharma A/S
ASND
|
-43.41 | $ 217.23 | -0.38 % | $ 5 B |  Danmark |
 |
Aurinia Pharmaceuticals
AUPH
|
36.26 | $ 13.92 | -4.4 % | $ 1.87 B | Canada |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
12.44 | $ 19.22 | -0.05 % | $ 898 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Coherus BioSciences
CHRS
|
275.39 | $ 1.65 | 0.61 % | $ 193 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
-123.35 | $ 0.66 | 9.41 % | $ 7.56 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
CytomX Therapeutics
CTMX
|
-17.54 | $ 4.26 | -4.48 % | $ 588 M | USA |
 |
Avenue Therapeutics
ATXI
|
-418.16 | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-51.64 | $ 1.41 | 0.36 % | $ 360 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
ChemoCentryx
CCXI
|
-46.05 | - | - | $ 3.74 B | USA |
 |
Exelixis
EXEL
|
36.21 | $ 41.18 | -0.56 % | $ 11.2 B | USA |
 |
Aytu BioScience
AYTU
|
-71.51 | $ 2.63 | - | $ 16.5 M | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
-59.8 | - | - | $ 867 M | Germany |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Fulcrum Therapeutics
FULC
|
-21.46 | $ 6.71 | -2.61 % | $ 425 K | USA |
 |
Genmab A/S
GMAB
|
24.88 | $ 25.65 | -0.14 % | $ 16.3 B | Danmark |
 |
Bellerophon Therapeutics
BLPH
|
-782.6 | - | -74.18 % | $ 955 K | USA |
 |
Grifols, S.A.
GRFS
|
9.2 | $ 7.7 | 0.07 % | $ 6.83 B |  Spain |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Halozyme Therapeutics
HALO
|
649.18 | $ 62.24 | -0.99 % | $ 7.46 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
-43.75 | $ 4.25 | -3.96 % | $ 814 M | Canada |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
Immatics N.V.
IMTX
|
1.79 | $ 9.35 | -1.74 % | $ 588 M | Germany |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Brickell Biotech
BBI
|
-57.34 | - | -5.38 % | $ 6.06 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Calithera Biosciences
CALA
|
-1373.04 | - | -10.95 % | $ 876 K | USA |